To confirm this, we precipitated m6A modified RNAs with m6A antibody and found IGFL2-AS1 fragments were noticeably enriched in both OSRC-2 and A498 cells, which were hardly precipitated with m6A antibody in pazopanib resistant controls (Fig. 5B), suggesting IGFL2-AS1 preferred to be m6A modified in pazopanib sensitive ccRCC cells and these modifications were lost upon chronic pazopanib treatment. This evidence concerns the gene IGFL2 and nonpapillary renal cell carcinoma.